abstract |
A novel method of treating Parkinsonism, a novel method of treating depressions and a novel method of treating patients who have suffered cerebral strokes, by providing novel pharmaceutical compositions containing a specified fosfodiesterase inhibitor together with a specified known anti-Parkinson agent including dopa, m-tyrosine, apomorphine and ET 495. |